Chimeric virus of complete structural protein of hepatitis C virus and GB virus B

Abstract

The invention relates to a virus, a composition and the field of preparation or purification thereof, in particular to a chimeric virus of the complete structural protein of a hepatitis C virus and a GB virus B. The chimeric virus is formed by connecting the sequence of a non-coding region on the 5' terminal of the GB virus B, the gene sequence of the complete structural protein of the hepatitis C virus, a nonstructural protein of the GB virus B and the sequence of a non-coding region on a 3' terminal in turn, wherein the gene sequence of the complete structural protein of the hepatitis C virus is the gene sequence of the complete structural protein of 1b genotype hepatitis C virus. The chimeric virus can be used to infect marmoset effectively through the intrahepatic or intravenous injection of the chimeric virus-containing serum of a primary marmoset. The chimeric virus simulates the infection and immune state of the hepatitis C virus in bodies of primates, a platform for testing and evaluating the immunity to the complete structural protein of the hepatitis C virus is provided, and the scientific problems such as limitation on the research on immunity, prevention and control ofhepatitis C virus and vaccine evaluation due to lack of small infected models of primates are solved.

Description

technical field [0001] The present invention relates to the field of virus, composition and its preparation or purification, in particular to the field of virus modified by introducing foreign gene material. Background technique [0002] At present, there are about 170 million people infected with hepatitis C virus (Hepatitis C Virus, HCV) worldwide. Hepatitis C virus is one of the main pathogenic factors of acute / chronic hepatitis transmitted by blood. The prevalence of HCV infection varies greatly around the world, especially in developing countries. 50-85% of hepatitis C virus infected patients develop into chronic hepatitis, 10-20% of them further develop into complex chronic liver diseases such as liver cirrhosis, and 1-5% develop into liver cancer after 20 or 30 years. However, there is still a lack of very effective therapeutic drugs for hepatitis C virus infection at present, and what is more serious is that there is no hepatitis C preventive vaccine in the world so...

AI Technical Summary

Problems solved by technology

However, GB virus B is still different from hepatitis C virus, and cannot completely simulate the infection and immune status of hepatitis C virus in primates. Therefore, if the GB virus B genome is used as the backbone, the function of hepatitis C virus The gene replaces the corresponding functional region of GB virus B to construct the HCV / GBV-B chimeric virus, which is an ideal solution to study the immunity of hepatitis C virus by using the infection model

However, there are certain difficulties in replacing the complete functional protein gene of hepatitis C virus into the GB virus B genome, and there are uncertainties and risks in whether the constructed chimeric virus with complete functional protein can infect small primates Therefore, the current research using HCV / GBV-B chimeric virus has only been found in the replacement of the 5'-NCR, p7 or HVR1 of the hepatitis C virus with smaller gene segments into the GB virus B genome, which only contains C Chimeric viruses with very short gene segments of hepatitis virus can only be used to study the function of these specific gene segments, and cannot show the interaction between hepatitis C virus and the host, and cannot completely simulate the interaction of hepatitis C virus in primates immune response

Images